Additional file 2: of Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes

Multivariable-adjusted associations of allopurinol use with composite outcome (MI or stroke) for prevalent allopurinol users* with gout and diabetes, with previous allopurinol users as the reference category. This file provides the results of sensitivity analyses, repeating the main analysis in prevalent allopurinol users, instead of incident allopurinol users. (DOC 31 kb

Additional file 1: of Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes

International Classification for Diseases, Ninth revision, Clinical Modification (ICD-9-CM) Diagnostic Codes for each condition used for outcome, cohort eligibility, and covariate definitions. This file provides the ICD-9-CM codes for underlying conditions, study outcomes and covariates. (DOC 43 kb

Additional file 1:Table S1. of A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial

SCP categories and medical history/diagnoses at baseline, with missing data handled by non-responder imputation (NRI). Table S2. Patients withdrawn from the study at/before and after week 12 due to lack of efficacy. Figure S1. Mean DAS28(ESR) score by SCP status, with missing data handled by last observation carried forward (LOCF). Full analysis set. (DOCX 1302 kb

Additional file 2: of Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis

Patient identification results. (DOCX 15 kb

Additional file 1: of Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry

Table S1 describes the rates of remaining on drug, switching, and discontinuing without starting a new biologic in the TCZ and ABA groups before and after match. Table S2 presents the distribution of prednisone dose increases and decreases between the matched TCA and ABA initiators based on the baseline prednisone usage. Table S3 presents rates of discontinuation and initiation of cDMARDs over the 6-month follow-up. (DOCX 14 kb

Additional file 2: of Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Adjusted HR for time to serious infection in patients censored after they stopped/switched their initial therapy (n = 21,832). (DOCX 14 kb

Additional file 1: of Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Proportion and adjusted risk ratio of patients who achieved therapy effectiveness based on the modified algorithm (n = 16,305). (DOCX 14 kb

Additional file 1: Table S1. of Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

Glossary. Description of data: Glossary of vaccination terminology. (DOCX 28 kb

Additional file 2: Table S2. of Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

Relationship of baseline factors with pneumococcal and influenza immunologic responses stratified by age (<55 or ≥55 years). Description of data: Pneumococcal and influenza vaccine responses are shown for patients <55 and ≥55 years according to baseline factors. (DOCX 29 kb

Additional file 3: Table S3. of Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

Geometric mean titers and immunologic response to individual antigens 28 dayspost-vaccination. Description of data: Pre-and post-vaccination geometric mean titers and immunologic responses are shown for individual pneumococcal and influenza vaccine antigens in patients without protective antibody levels at baseline. (DOCX 29 kb